Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.94
- Piotroski Score 6.00
- Grade N/A
- Symbol (EGF)
- Company BlackRock Enhanced Government Fund, Inc.
- Price $10.02
- Changes Percentage (-1.28%)
- Change -$0.13
- Day Low $9.97
- Day High $10.27
- Year High $11.51
BlackRock Enhanced Government Fund, Inc. is a closed-ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It primarily invests in a portfolio of United States government and government agency securities, including the U.S. government mortgage-backed securities. The fund invests in non U.S. government debt securities of foreign or domestic issuers, including commercial paper, notes, corporate bonds, debentures, asset-backed securities, mortgage-backed securities, corporate loans, sovereign debt securities, and money market securities. It was formerly known as Enhanced Government Fund, Inc. BlackRock Enhanced Government Fund, Inc. was formed in 2006 and is domiciled in United States.
- Last Earnings 09/03/2024
- Ex-Dividend for 5/16 Dividend 09/16/2024
- Dividend Payable 09/30/2024
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.45
- Trailing P/E Ratio 20.68
- Forward P/E Ratio 20.68
- P/E Growth 20.68
- Net Income $1.63 M
Income Statement
Quarterly
Annual
Latest News of EGF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
A study by Johnson & Johnson revealed a pre-medication regimen with dexamethasone significantly reduced infusion-related reactions with RYBREVANT for NSCLC patients, showing a three-fold decrease in r...
By Yahoo! Finance | 2 days ago -
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
Long-term data from the MARIPOSA study show improved outcomes with RYBREVANT plus LAZCLUZE™ compared to osimertinib in first-line treatment for NSCLC....
By Yahoo! Finance | 5 days ago -
Estimating The Fair Value Of Siegfried Holding AG (VTX:SFZN)
An analyst price target for Siegfried Holding AG (VTX:SFZN) is 20% above the fair value estimate. By using a Discounted Cash Flow (DCF) model, the company appears to be fairly priced based on future c...
By Yahoo! Finance | 1 month ago
